Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial.

Abstract

BACKGROUND:

Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, β-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180 days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress.

RESULTS:

Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p > 0.05) for any of the studied parameters. Final data analysis (supplement: n = 9; placebo: n = 10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p < 0.001). After treatment, a significant decrease (1.53-fold; p < 0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p < 0.05) and paraoxonase-1 (PON1) levels after 60 days of treatment (p < 0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120 days (p < 0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group.

CONCLUSIONS:

The combined administration of the supplement with hydrolyzed diet over 180 days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.

• Authors: Sergi Segarra, Silvia Martínez-Subiela, Marta Cerdà-Cuéllar, Daniel Martínez-Puig, Alberto Muñoz-Prieto, Fernando Rodríguez-Franco, Antonio Rodríguez-Bertos, Karin Allenspach, Alfonso Velasco, José Cerón
• Journal: BMC veterinary research (BMC Vet Res) Vol. 12 Pg. 49 (Mar 10 2016) ISSN: 1746-6148 [Electronic] England
• PMID: 26965834 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Prebiotics
• Chondroitin Sulfates

Topics

• Animals
• Chondroitin Sulfates (adverse effects, therapeutic use)
• Dog Diseases (drug therapy, therapy)
• Dogs
• Female
• Inflammatory Bowel Diseases (pathology, therapy, veterinary)
• Male
• Microbiota
• Prebiotics (adverse effects)